GE Healthcare has signed a licensing agreement with Australian biotech company AdAlta to develop antibodies for diagnostic imaging.
AdAlta will screen its human protein therapeutics library to identify antibodies that GE could use as imaging agents, beginning with granzyme B, an enzyme commonly secreted by immune cells in cancer.
The research effort could eventually help in the selection and monitoring of patients receiving immunotherapy, AdAlta said. Financial terms of the agreement were not disclosed.
